Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rebates, Pricing Pressure Weigh On J&J's Q1 Pharma Sales

Executive Summary

Johnson & Johnson had to offer steeper discounts in certain therapeutic categories like cardiovascular and metabolic disease, impacting first quarter sales. So far, the impact of a new biosimilar in the US has had minimal impact on Remicade.


Related Content

It's Not All About IO: Seven Drugs To Watch At ASCO
More Pressure On Pradaxa? US Payers May Narrow Coverage Of NOACs
Invokana Adds Warnings On Amputation Risk, But Will It Give Jardiance An Edge?
Lilly Shows Diabetes Dominance, But Will It Last?
Discounts Will Be Key Factor In US Uptake Of Samsung's Renflexis
1Q Pharma Results Preview: Biogen, Novartis, Lilly, Amgen, GSK, AstraZeneca, BMS, AbbVie, Roche, Bayer, Sanofi
Tylenol Delivers J&J Relief As Global 'Consumer Staples' Sales Slump
J&J’s $30bn For Actelion Buys Immediate And Longer-Term Value
Jardiance's Cardiovascular Benefit Claim Bodes Well For Other Products Too
Pfizer Will Support Inflectra Launch With Dedicated Sales Force


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts